• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Viruses . Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects

tetano

Editor, Senior Moderator
Viruses


. 2021 Apr 16;13(4):697.
doi: 10.3390/v13040697.
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects


Angela Huynh[SUP] 1 [/SUP], Donald M Arnold[SUP] 1 2 [/SUP], James W Smith[SUP] 1 [/SUP], Jane C Moore[SUP] 1 [/SUP], Ali Zhang[SUP] 3 4 5 [/SUP], Zain Chagla[SUP] 1 6 [/SUP], Bart J Harvey[SUP] 7 8 [/SUP], Hannah D Stacey[SUP] 3 4 5 [/SUP], Jann C Ang[SUP] 3 4 5 [/SUP], Rumi Clare[SUP] 1 [/SUP], Nikola Ivetic[SUP] 1 [/SUP], Vasudhevan T Chetty[SUP] 9 10 [/SUP], Dawn M E Bowdish[SUP] 1 3 4 [/SUP], Matthew S Miller[SUP] 3 4 5 [/SUP], John G Kelton[SUP] 1 2 [/SUP], Ishac Nazy[SUP] 1 2 [/SUP]



Affiliations

Abstract

Coronavirus Disease 2019 (COVID-19) is a global pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While detection of SARS-CoV-2 by polymerase chain reaction with reverse transcription (RT-PCR) is currently used to diagnose acute COVID-19 infection, serological assays are needed to study the humoral immune response to SARS-CoV-2. Anti-SARS-CoV-2 immunoglobulin (Ig)G/A/M antibodies against spike (S) protein and its receptor-binding domain (RBD) were characterized in recovered subjects who were RT-PCR-positive (n = 153) and RT-PCR-negative (n = 55) using an enzyme-linked immunosorbent assay (ELISA). These antibodies were also further assessed for their ability to neutralize live SARS-CoV-2 virus. Anti-SARS-CoV-2 antibodies were detected in 90.9% of resolved subjects up to 180 days post-symptom onset. Anti-S protein and anti-RBD IgG titers correlated (r = 0.5157 and r = 0.6010, respectively) with viral neutralization. Of the RT-PCR-positive subjects, 22 (14.3%) did not have anti-SARS-CoV-2 antibodies; and of those, 17 had RT-PCR cycle threshold (Ct) values > 27. These high Ct values raise the possibility that these indeterminate results are from individuals who were not infected or had mild infection that failed to elicit an antibody response. This study highlights the importance of serological surveys to determine population-level immunity based on infection numbers as determined by RT-PCR.

Keywords: COVID-19; SARS-CoV-2; antibody; serology.
 
Back
Top Bottom